Abstract
Prostate cancer is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related deaths in Western civilization. Although localized prostate cancer can be treated effectively in different ways, almost all patients progress to the incurable metastatic castration-resistant prostate cancer. Due to the significant mortality and morbidity rate associated with the progression of this disease, there is an urgent need for new and targeted treatments. In this review, we summarize the recent advances in research on identification of prostate tissue-specific antigens for targeted therapy, generation of highly specific and selective molecules targeting these antigens, availability of therapeutic radionuclides for widespread medical applications, and recent achievements in the development of new-generation small-molecule inhibitors and antibody-based strategies for targeted prostate cancer therapy with alpha-, beta-, and Auger electron-emitting radionuclides.
Highlights
According to the cancer epidemiology databases provided by the International Agency for Research on Cancer and the WHO Cancer Mortality Database, prostate cancer is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related deaths in Western civilization [1].Today, standard primary therapy for patients with localized prostate cancer consists mainly of radical prostatectomy and/or external beam radiotherapy or brachytherapy
We summarize the recent advances in research on identification review, we summarize the recent advances in research on identification of prostate tissue-specific of prostategeneration tissue-specific antigens, generation of highlymolecules specific and selective molecules targeting these antigens, of highly specific and selective targeting these antigens, availability antigens, availability of therapeutic radioisotopes for widespread medical applications and recent of therapeutic radioisotopes for widespread medical applications and recent achievements in the achievements development of aofnew generation of antibody-based strategies and small-molecule development in ofthe a new generation antibody-based strategies and small-molecule inhibitors for inhibitors for targeted prostate cancer therapy with alphaand beta-particle radionuclides
J415 and J591 manner by anti-PSMA antibody (mAb) competed for binding to Prostate-Specific Membrane Antigen (PSMA) antigen, J533 did not interfered with J415, rapid elimination of 131 I
Summary
According to the cancer epidemiology databases provided by the International Agency for Research on Cancer and the WHO Cancer Mortality Database, prostate cancer is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related deaths in Western civilization [1]. Localized prostate cancer can be treated effectively by these therapies, almost all patients progress to metastatic castration-resistant prostate cancer (mCRPC) [4]. We summarize the recent advances in research on identification review, we summarize the recent advances in research on identification of prostate tissue-specific of prostategeneration tissue-specific antigens, generation of highlymolecules specific and selective molecules targeting these antigens, of highly specific and selective targeting these antigens, availability antigens, availability of therapeutic radioisotopes for widespread medical applications and recent of therapeutic radioisotopes for widespread medical applications and recent achievements in the achievements development of aofnew generation of antibody-based strategies and small-molecule development in ofthe a new generation antibody-based strategies and small-molecule inhibitors for inhibitors for targeted prostate cancer therapy with alphaand beta-particle radionuclides. Targeted prostate cancer therapy with alpha- and beta-particle radionuclides
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
